HC Wainwright restated their buy rating on shares of CervoMed (NASDAQ:CRVO – Free Report) in a research report sent to investors on Wednesday morning,Benzinga reports. HC Wainwright also issued estimates for CervoMed’s Q4 2026 earnings at ($0.59) EPS, FY2026 earnings at ($2.70) EPS, Q1 2027 earnings at ($0.51) EPS, Q2 2027 earnings at ($0.46) EPS, […]

Compass Pathways (NASDAQ:CMPS – Get Free Report)‘s stock had its “buy” rating reiterated by analysts at HC Wainwright in a research report issued to clients and investors on Wednesday,Benzinga reports. They currently have a $70.00 price target on the stock. HC Wainwright’s price objective would indicate a potential upside of 432.81% from the company’s current […]